Doctor Alex says Ozempic works but comes with a catch, and walks through what he thinks people misunderstand about GLP-1 drugs.
Recap by typeshit. Full story at Doctor Alex .
The clinic says the choice should weigh long term outcomes and overall health, not just pounds lost, and that no single treatment fits everyone.
Lilly reports on Oct. 29, and Zacks expects investors to focus on Foundayo after the oral GLP-1 brought in $98 million in its first full quarter on sale.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
A Williamsburg shop sells injectable peptide vials for around $95 each, while the FDA has sent warning letters to sellers relying on the same label.
9:07
The endocrinologist takes on whether people can get retatrutide now, setting gray market supply against the results from Lilly's actual trials.
Loading…